| Literature DB >> 19032103 |
Mark R Underwood1, Lisa L Ross, David M Irlbeck, Peter Gerondelis, Elizabeth Rouse, Marty H St Clair, Lan Trinh, Neil Parkin, E Randall Lanier.
Abstract
Thymidine-sparing triple-nucleoside regimens have exhibited poor virologic response despite apparent phenotypic susceptibility to 2 of 3 regimen components at early time points. Phenotypic resistance masking by wild-type virus may explain this discrepancy.Consistent with this notion were (1) the presence of low level nucleoside reverse-transcriptase inhibitor-resistant human immunodeficiency virus in subjects receiving failing first-line regimens consisting of tenofovir (TDF), abacavir (ABC), and lamivudine (3TC); (2) lower fold resistance associated with mixtures versus mutants in a clinical-isolate database; and (3) dose dependent changes in susceptibility to ABC, 3TC, TDF, and didanosine on titration of K65R and/or M184V with wild-type virus. These findings underscore the limitations of stand-alone phenotypic susceptibility measures and emphasize the importance of complementary and/or more sensitive techniques.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19032103 DOI: 10.1086/595296
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226